Patients with acute myeloid leukemia (AML) in remission for 3 years have survival rates similar to the general population, but long-term needs remain poorly understood. A retrospective analysis showed ...
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
SEATTLE, WA / ACCESS Newswire / March 20, 2025 / Aptevo Therapeutics (APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ...
New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
The MarketWatch News Department was not involved in the creation of this content. 100% of patients in Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design underpins a ...
The study covered in this summary was published on ssrn.com as a preprint and has not yet been peer reviewed. Cytarabine plus an anthracycline has been the standard AML induction regimen for decades, ...
In a randomized phase 2 study of 79 patients with acute myeloid leukemia (AML) in first complete remission, nivolumab maintenance therapy did not improve progression-free survival (13.2 vs 10.9 months ...
Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...
90% of frontline AML patients achieved remission with mipletamig plus ven/aza, surpassing the 66% rate seen with ven/aza alone. No cytokine release syndrome (CRS) has been reported in the RAINIER ...
Aptevo Therapeutics (APVO) announced two additional frontline AML patients have achieved remission within 30 days of treatment in the Company’s RAINIER dose optimization trial evaluating mipletamig in ...
Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...
SEATTLE, WA / ACCESS Newswire / September 16, 2025 / Aptevo Therapeutics ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific ...
A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results